MediWound (MDWD) Q2 2026: EscharEx Phase III Progress and NexoBrid BARDA Deal Drive Strategic Momentum
MediWound advanced its EscharEx Phase III VALUE trial toward key milestones while securing a master services agreement with Vericel under a significant BARDA contract for NexoBrid development. Despite near-term revenue pressure from timing of government-funded programs, the company reaffirmed full-year guidance supported by expanding commercial traction and pipeline opportunities.
Summary
- Clinical Development Execution: EscharEx Phase III enrollment and interim assessment remain on track for Q1 2027.
- Commercial Expansion: NexoBrid achieved record US sales with growing adoption across burn centers.
- Government Partnerships: BARDA-backed master services agreement with Vericel enhances development and revenue visibility.
Business Overview
MediWound is a biotechnology company specializing in enzymatic therapies for tissue repair, primarily through its FDA-approved biologic NexoBrid for burn eschar removal and its late-stage pipeline product EscharEx targeting chronic wound debridement. The company generates revenue from product sales, government contracts, and development services, with major focus areas including chronic wound care and burn treatment markets.
Performance Analysis
MediWound reported second quarter revenue of $3.1 million, down from $5.7 million year-over-year, primarily due to the timing of BARDA-funded development revenue. Gross margin contracted to 10.9% from 23.5% last year, impacted by a one-time facility scale-up cost. Operating loss widened to $9.5 million from $5.7 million, reflecting increased R&D spend on the EscharEx Phase III VALUE trial and modest SG&A expense growth.
Despite the lower revenue base, net loss improved to $7.4 million or $0.57 per share from $13.3 million or $1.23 per share, largely driven by non-cash financial income related to warrant revaluation. Adjusted EBITDA loss expanded to $8.3 million from $4.5 million, underscoring higher investment in clinical development and operational scale-up.
- Revenue Pressure from BARDA Timing: Revenue decline reflects shifting BARDA development revenue recognition, with second-half weighted contributions expected.
- Increased R&D Investment: $5.9 million spent on clinical trials, emphasizing commitment to advancing EscharEx as a key long-term growth driver.
- Balance Sheet Strength: $36 million in cash and equivalents supports ongoing development and operational activities despite $20 million cash burn in H1.
Overall, MediWound is navigating near-term revenue volatility while strategically investing in its pipeline and commercial infrastructure to position for sustainable growth.
Executive Commentary
"The EscharEx Phase III VALUE trial is advancing across the U.S., Europe, and Israel, with the interim sample size reassessment and completion of enrollment expected by the end of the first quarter of 2027."
Ofer Gonen, Chief Executive Officer
"VeriCell reported NexoBrid’s strongest quarter since launch, with record quarterly revenue, hospital unit sales and ordering centers, reflecting continued adoption and increasing utilization across the U.S. burn care market."
Ofer Gonen, Chief Executive Officer
Strategic Positioning
1. Advancing EscharEx as a Market-Defining Chronic Wound Therapy
MediWound is prioritizing execution of its global Phase III VALUE trial with a target enrollment of 216 patients across 40 sites. The trial’s progress toward an interim sample size reassessment and enrollment completion by Q1 2027 is critical for regulatory milestones and commercial validation. The inclusion of pressure ulcers in the market opportunity expands the addressable market to an estimated $1.05 billion peak U.S. sales, reflecting significant upside potential beyond venous leg ulcers. An investigator-initiated pressure ulcer study slated for Q4 2026 further broadens clinical evidence supporting EscharEx’s differentiated enzymatic debridement profile.
2. Leveraging BARDA Partnership to Expand NexoBrid’s Commercial and Development Footprint
The 10-year, up to $197 million BARDA contract awarded to Vericel and the subsequent master services agreement with MediWound underpin a multi-faceted strategy to enhance NexoBrid’s role in burn care and national preparedness. Revenue recognition from development programs, including next-generation formulations targeting blast and friction injuries, is expected to commence in H2 2026. This government-backed funding mitigates commercial risk and supports ongoing innovation, including a room temperature stable NexoBrid formulation funded by the Department of War.
3. Manufacturing Scale-Up and Regulatory Readiness
MediWound is implementing operational modifications requested by the European Medicines Agency (EMA) following a pre-audit of its expanded NexoBrid manufacturing facility. Completion is anticipated by Q4 2026, with commercial supply approval targeted for H2 2027. The company maintains that these changes are operational rather than related to product quality, indicating manageable regulatory risk. This scale-up is essential to meet growing demand and support broader market penetration in Europe and the U.S.
4. Expanding Clinical Pipeline Beyond Venous Leg Ulcers
Alongside EscharEx’s pivotal trial, MediWound is preparing to initiate a Phase II diabetic foot ulcer (DFU) study in Q4 2026, following constructive regulatory feedback. This trial aims to enroll 50 patients with a primary endpoint focused on time to complete debridement, leveraging EscharEx’s enzymatic efficacy. Positive outcomes could unlock further label expansions and commercial opportunities in large chronic wound segments.
5. Commercial Traction and Market Adoption Dynamics
NexoBrid’s growing adoption across approximately 80 U.S. burn centers demonstrates increasing utilization and market penetration. The company notes no capacity constraint on demand, with inventory currently limited by manufacturing readiness rather than sales appetite. The reimbursement environment remains stable, with no updates on CPT coding, but the broad distribution across acute care, clinics, and nursing facilities aligns well with MediWound’s go-to-market strategy for EscharEx.
Key Considerations
MediWound’s second quarter underscores a strategic balancing act between investing heavily in late-stage clinical development and managing near-term revenue fluctuations driven by government contract timing.
- Clinical Milestones Drive Valuation: On-track enrollment and interim analysis of the Phase III VALUE trial are pivotal for investor confidence and regulatory progress.
- Government Funding as Revenue Catalyst: The BARDA contract and Department of War funding provide non-dilutive capital and revenue streams that de-risk development and commercialization.
- Manufacturing Scale-Up Risks: While EMA modifications are operational, any delays could impact supply timing and revenue recognition beyond 2027.
- Competitive Landscape Awareness: MediWound acknowledges potential competition from new entrants but highlights EscharEx’s advanced clinical stage and enzymatic speed advantage.
- Cash Burn and Capital Management: With $36 million cash and $20 million burn in H1, capital discipline remains essential to sustain development programs through key inflection points.
Risks
MediWound faces execution risks inherent to clinical trials, including enrollment pace and regulatory feedback that could delay product approvals. Manufacturing scale-up and regulatory inspections pose operational risks that could defer commercial supply. Competitive threats from emerging enzymatic debridement therapies may pressure market share if they advance clinically. Additionally, reliance on government contracts introduces revenue timing variability and dependency on continued funding.
Forward Outlook
For Q3 2026, MediWound anticipates ongoing clinical trial enrollment and preparatory activities for new investigator-initiated studies. The company expects to begin recognizing revenue from the Vericel master services agreement and other government-funded programs in H2 2026.
- Full-year 2026 revenue guidance reaffirmed at $24 million to $26 million, weighted toward second-half contributions.
- Completion of EMA-requested manufacturing modifications targeted for Q4 2026, enabling commercial supply approval in H2 2027.
Management emphasizes disciplined execution on clinical milestones and scaling commercial operations to support long-term value creation.
Takeaways
MediWound is advancing its strategic priorities with clear progress in clinical development and commercial partnerships, though near-term financials reflect timing shifts and elevated investments.
- Clinical Execution Confidence: Maintaining enrollment timelines and achieving interim data readouts in early 2027 will be critical for EscharEx’s regulatory and commercial trajectory.
- Government Collaboration as Growth Lever: The BARDA contract and MSA with Vericel provide diversified revenue streams and validation for NexoBrid’s expanding market role.
- Watch Manufacturing and Regulatory Progress: Completion of EMA facility modifications and subsequent approvals will unlock supply capacity essential for scaling sales in 2027 and beyond.
Conclusion
MediWound’s Q2 2026 results reflect a company investing heavily in late-stage clinical development and leveraging government partnerships to expand its enzymatic debridement franchise. While revenue pressures persist due to timing of contract revenues, the strategic roadmap and operational progress position the company for meaningful growth as clinical milestones and manufacturing scale-up converge in the coming year.
Industry Read-Through
MediWound’s experience highlights the critical role of government contracts in supporting biotech innovation for specialized therapeutic areas such as burn care and chronic wounds. The company’s enzymatic debridement approach and its expansion into broader wound types reflect a growing trend of biologic therapies targeting complex tissue repair markets. The emphasis on manufacturing scale-up and regulatory readiness underscores common industry challenges in transitioning from clinical success to commercial supply. Investors and industry participants should monitor how regulatory agencies engage with novel enzymatic therapies and how government funding shapes competitive dynamics in wound care.